MFDS national lot release regulation
Regulation on Designation, Approval Procedure and Method of National Lot Release Drugs
Current edition
MFDS Notice 2025-77 of November 28, 2025, in force November 29, 2025
Current edition
MFDS Notice 2025-77 of November 28, 2025, in force November 29, 2025
About this standard
Sets which drugs need national lot release, the application, the review of documents, the testing and the approval procedure.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
South Korea
- National lot release of vaccines, plasma derivatives, antitoxins, botulinum and tuberculin productsLot release and sample testing · Sample testing
Related standards: MHRA Responsible Person (import) guidance, EudraLex Volume 4 Annex 16, HC Lot Release Program guidance, TGA vaccine batch release, MFDS imported drug management regulation, RDC 669/2022, RDC 670/2022, RDC 900/2024, RDC 944/2024, SFDA lot release policy, Taiwan biological product lot release regulations. See all standards.